Pharmaceutical Novavax announced this Wednesday (8) that it will start a new study to evaluate a vaccine against two diseases at once: the common flu and COVID-19. The mixture would be especially useful if the scenario of annual booster vaccination against the SARS-CoV-2 coronavirus is confirmed.
The surveys will start in Australia, with a total of 640 adults. The age of the participants varies between 50 and 70 years, and only those who have already been vaccinated against COVID-19 or previously contracted the disease will be selected.
The volunteers will receive a combination of the company’s immunizing agent against COVID-19, NVX-CoV2373, and the influenza vaccine created by Novavax, called Nanoflu.
Want to catch up on the best tech news of the day? Access and subscribe to our new youtube channel, Canaltech News. Everyday a summary of the main news from the tech world for you!
To date, Novavax’s vaccine against COVID-19 has not been used on a large scale, despite showing promise. In phase 3 clinical trials, the company has already reported 90% efficacy. The company is betting on a technology different from those already in wide use against the disease, using protein subparticles, which present protein S to the immune system.
The company has good prospects for the double vaccine. The combination has already shown good potential in the pre-clinical stages, which supported the advancement of studies for human participants.
Novavax had already stated in May this year that it has the perspective that the combination of NVX-CoV2373 and Nanoflu will be crucial for the future, to prevent new outbreaks, protect against new variants, as well as being more efficient for healthcare systems around the world.
Did you like this article?
Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.